Characterization of biomarkers in moderate to severe COVID19 in pediatric patients
Article Sidebar
Article Details
Authors
Publication Information
Keywords
Children
COVID19
Abstract
Abstract
Aim: To know the behavior of the biomarkers associated with moderate to severe COVID19 disease in boys and girls.
Materials and Methods: A case series descriptive study. All patients who consulted the pediatric emergency service were included, they must have a polymerase chain-reverse transcriptase test (RT-PCR) positive for SARS-CoV-2 from January to August 2021 and required hospitalization for presenting a moderate to severe clinical case of COVID19.
Results: 40 patients with a diagnosis of moderate to severe COVID19 were included for analysis, of these 19 patients were boys and 21 girls, with a mean age for the entire group of 71 months. Among the biomarkers clearly associated with disease progression, the most affected were C-reactive protein 43 mg.dl-1, ferritin 435 ng.ml-1, procalcitonin 7.2 ng.dl-1, D-dimer 3.486 ng.dl-1, IL -6 49 pg.ml-1
Conclusion: The biomarkers most affected in the group studied were C-reactive protein, ferritin, procalcitonin, D-dimer and IL-6, hematometric parameters as well as other biomarkers such as albumin, liver enzymes, serum sodium and triglycerides did not present abnormality. There were no statistically significant differences between boys and girls, except for the platelets parameter (p 0.006).
Graph - Number of readers per month
Downloads
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 |
This work is licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
| Copyright notice |
 |
Authors will retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to a Creative Commons Attribution-Noncommercial-ShareAlike 4.0 International license (CC BY-NC-SA 4.0) that allows third parties to share the work as long as its author and its first publication in this magazine are indicated. |
|
Authors may adopt other non-exclusive license agreements for the distribution of the version of the published work (eg: deposit it in an institutional repository or publish it in a monographic volume) provided that the initial publication in this journal is indicated. |
|
Authors are allowed and recommended to disseminate their work through the internet (eg, in institutional telematic files or on their website) before and during the submission process, which can lead to interesting exchanges and increase citations of the published work. (See The effect of open access). |
| About the Creative Commons license |
|
|
You are free to: |
|
Share — copy and redistribute the material in any medium or format. |
|
Adapt — remix, transform, and build upon the material. |
|
The licensor cannot revoke these freedoms as long as you follow the license terms. |
Under the following terms: |
 |
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. |
 |
NonCommercial — You may not use the material for commercial purposes. |
 |
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. |
| No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. |